LSD and the Aging Brain: A Paper Worth Sitting With

Yesterday Bryan Johnson asked a question a lot of us felt the moment we saw it: LSD as a longevity therapy?

The reason the question has weight is a paper that appeared the day before, on November 10, in Aging Cell. Aurora Savino and her colleagues at Human Technopole in Milan and the University of Turin published a study with a title that says exactly what they found: lysergic acid diethylamide induces transcriptional changes opposing signatures of brain ageing and neurodegeneration.

In plain language, here is what that means.

When rats received LSD over a stretch of time, the pattern of gene activity in the brain ran in the opposite direction of what happens as the human prefrontal cortex ages. Genes that usually go quiet with age lit up. Genes that usually rise with age settled down. A single dose in mice produced the same kind of opposing pattern, across several dose levels.

The researchers also compared that effect with other interventions, including physical exercise. In their analysis, LSD's opposition to the aging signature ran stronger than exercise, and stronger than a wide range of other compounds they tested.

The gene networks LSD turned on are the ones involved in neuroplasticity and neuronal communication — the brain's capacity to form new connections and keep existing ones healthy. Those are the same systems that tend to fade as we get older. In cortical cells, LSD also reduced the structural and molecular damage caused by amyloid-beta, the protein associated with Alzheimer's. Dendrites looked healthier. Synaptic markers returned toward their usual levels. The picture is of a system moving back toward resilience.

For people who already work with these medicines, this is more than a laboratory curiosity. For years, people have come to LSD, psilocybin, ayahuasca, and related medicines seeking relief, insight, or a deeper relationship with themselves. Many leave describing not only a change in mood, but a feeling that something in the mind has become more flexible, more alive. This paper gives that lived experience a molecular vocabulary. It suggests these compounds may engage the very programs the aging brain lets go of — and that the conversation about psychedelics is widening, from mood and meaning into longevity, cognition, and how the brain stays itself across a lifetime.

That widening is the part we find most moving. Wellness and consciousness work have always been about more than feeling better this week. They are about staying available to your own life: curious, connected, able to change. A medicine that speaks to the aging signature of the brain belongs in that conversation.

At Lotus Mind Medicine, this sits close to the heart of what we call Psyenthogenics: meeting the mind (psy) and the divine within (entheo) with care, science, and guided presence. Christian Lé, MD, and our team offer guided Psyenthogenic therapy because the medicine is only part of the work. Preparation, a trusted container, and integration afterward are how a powerful experience becomes a lasting change.

We also host 7-night retreats on Costa Rica's Pacific coast, including for couples — a setting where this kind of work can unfold with time, nature, and support.

If this news stirs something in you — curiosity, recognition, a sense that the field is catching up to a bigger idea of what these medicines can do — we would be glad to talk.

Visit lotusmindmedicine.com, or learn about retreats at lotusmindretreats.com.

The paper is open access: https://doi.org/10.1111/acel.70793.